简要报告：奥希替尼联合卡马替尼用于一线治疗进展后MET改变的EGFR突变非小细胞肺癌患者 - Suppr

Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.

作者信息

Elghawy Omar, Barsouk Adam, Reed-Guy Lauren, Stalker Margaret, Sussman Jonathan, Robinson Kyle, Kosteva John, Singh Aditi, Cohen Roger B, Langer Corey, Ciunci Christine, D'Avella Christopher, Sun Lova, Marmarelis Melina E, Aggarwal Charu

机构信息

Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA..

出版信息

Clin Lung Cancer. 2025 Mar;26(2):158-163.e2. doi: 10.1016/j.cllc.2024.11.014. Epub 2024 Dec 13.

DOI:10.1016/j.cllc.2024.11.014

PMID:39743378

Abstract

摘要

相似文献

Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.简要报告：奥希替尼联合卡马替尼用于一线治疗进展后MET改变的EGFR突变非小细胞肺癌患者

Clin Lung Cancer. 2025 Mar;26(2):158-163.e2. doi: 10.1016/j.cllc.2024.11.014. Epub 2024 Dec 13.

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.简短报告：表皮生长因子受体（EGFR）突变且间充质上皮转化因子（MET）扩增的非小细胞肺癌患者对奥希替尼联合MET抑制剂的临床反应、毒性及耐药机制

JTO Clin Res Rep. 2023 Jun 1;4(8):100533. doi: 10.1016/j.jtocrr.2023.100533. eCollection 2023 Aug.

Osimertinib and Capmatinib Combination Therapy to Overcome Y1003N-Mediated Resistance in -Mutant NSCLC: A Case Report.奥希替尼与卡马替尼联合治疗克服Y1003N介导的EGFR突变型非小细胞肺癌耐药：一例报告

JTO Clin Res Rep. 2022 Aug 5;3(10):100396. doi: 10.1016/j.jtocrr.2022.100396. eCollection 2022 Oct.

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.MET 抑制剂卡马替尼通过抑制非小细胞肺癌中的 MET/Akt/snail 信号通路和减少癌相关成纤维细胞的生成来克服奥希替尼耐药。

Aging (Albany NY). 2021 Feb 17;13(5):6890-6903. doi: 10.18632/aging.202547.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.表皮生长因子受体（EGFR）抑制剂治疗失败的 EGFR 突变、MET 因子失调的非小细胞肺癌患者中卡马替尼（INC280）联合吉非替尼的 Ib/II 期研究。

J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).双重 MET 和 ERBB 抑制克服奥希替尼耐药晚期非小细胞肺癌（NSCLC）中的肿瘤内可塑性。

Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

Capmatinib for the treatment of non-small cell lung cancer.卡马替尼治疗非小细胞肺癌。

Expert Rev Anticancer Ther. 2019 Aug;19(8):659-671. doi: 10.1080/14737140.2019.1643239. Epub 2019 Aug 1.

MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.在具有EGFR突变和获得性MET改变的非小细胞肺癌患者中，MET酪氨酸激酶抑制剂与EGFR酪氨酸激酶抑制剂联合使用：一项系统评价和荟萃分析。

BMC Cancer. 2025 Apr 18;25(1):732. doi: 10.1186/s12885-025-14145-5.

Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.奥希替尼联合或不联合 savolitinib 治疗初治 MET 外显子 14 跳跃突变、EGFR 突变型晚期非小细胞肺癌的 II 期、随机、开放标签、两队列多中心干预研究的设计和原理： FLOWERS 试验。

Clin Lung Cancer. 2023 Jan;24(1):82-88. doi: 10.1016/j.cllc.2022.09.009. Epub 2022 Sep 30.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.奥希替尼联合 savolitinib 治疗 EGFR 突变阳性、MET 扩增的非小细胞肺癌患者：EGFR 酪氨酸激酶抑制剂进展后的多中心、开放标签、Ib 期研究的中期结果。

Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3.

引用本文的文献

The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.卡马替尼的药代动力学及其在非小细胞肺癌治疗中的疗效：一篇叙述性综述。

Transl Lung Cancer Res. 2025 Jul 31;14(7):2842-2852. doi: 10.21037/tlcr-2025-700. Epub 2025 Jul 28.

Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.克服表皮生长因子受体（EGFR）突变型肺癌对奥希替尼耐药的策略

Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献